UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer

Clinical cancer research, 2018-07, Vol.24 (14), p.3253-3262

2018

Volltextzugriff (PDF)

Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma

Investigational new drugs, 2021-08, Vol.39 (4), p.1081-1088

2021

Volltextzugriff (PDF)

A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia

Journal of hematology and oncology, 2017-03, Vol.10 (1), p.73-73, Article 73

2017

Volltextzugriff (PDF)

Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study

Clinical cancer research, 2010-12, Vol.16 (24), p.6150-6158

2010

Volltextzugriff (PDF)

Elimination of [14C] LY3023414 by aldehyde oxidase and CYP enzymes in humans following oral administration

Drug metabolism and pharmacokinetics, 2019-01, Vol.34 (1), p.S63-S63

2019

Volltextzugriff (PDF)

Oral Administration of Gemcitabine in Patients with Refractory Tumors: A Clinical and Pharmacologic Study

Clinical cancer research, 2008-06, Vol.14 (11), p.3477-3486

2008

Volltextzugriff (PDF)

Association of Long-term Administration of the Survivin mRNA-Targeted Antisense Oligonucleotide LY2181308 With Reversible Kidney Injury in a Patient With Metastatic Melanoma

American journal of kidney diseases, 2011-02, Vol.57 (2), p.300-303

2011

Volltextzugriff (PDF)

Children’s strategies in complex arithmetic

Journal of experimental child psychology, 2009-05, Vol.103 (1), p.49-65

2009

Volltextzugriff (PDF)

Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients

Theranostics, 2011-01, Vol.1 (1), p.290-301

2011

Volltextzugriff (PDF)

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship

Cancer chemotherapy and pharmacology, 2022-08, Vol.90 (2), p.137-148

2022

Volltextzugriff (PDF)

Targeting the hepcidin–ferroportin pathway in anaemia of chronic kidney disease

British journal of clinical pharmacology, 2019-05, Vol.85 (5), p.935-948

2019

Volltextzugriff (PDF)

Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer

Clinical cancer research, 2022-06, Vol.28 (11), p.2237-2247

2022

Volltextzugriff (PDF)

Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials

Clinical cancer research, 2022-06, Vol.28 (11), p.2297-2305

2022

Volltextzugriff (PDF)

A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979)

Cancer chemotherapy and pharmacology, 2003-02, Vol.51 (2), p.107-118

2003

Volltextzugriff (PDF)

A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer

Clinical cancer research, 2011-10, Vol.17 (20), p.6582-6591

2011

Volltextzugriff (PDF)

First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

Clinical cancer research, 2021-12, Vol.27 (24), p.6666-6676

2021

Volltextzugriff (PDF)

Abstract P142: Preclinical characterization of LOX-22783, a highly potent, mutant-selective and brain-penetrant allosteric PI3Kα H1047R inhibitor

Molecular cancer therapeutics, 2021-12, Vol.20 (12_Supplement), p.P142-P142

2021

Volltextzugriff (PDF)

A Randomised Phase 2 Study Combining LY2181308 Sodium (Survivin Antisense Oligonucleotide) with First-line Docetaxel/Prednisone in Patients with Castration-resistant Prostate Cancer

European urology, 2014-03, Vol.65 (3), p.516-520

2014

Volltextzugriff (PDF)

Safety and tolerability of the dual PI3K/mTOR inhibitor LY3023414 in combination with fulvestrant in treatment refractory advanced breast cancer patients

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.1064-1064

2017

Volltextzugriff (PDF)

Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.5009-5009

2019

Volltextzugriff (PDF)

A phase Ib study of prexasertib, a checkpoint kinase (CHK1) inhibitor, and LY3023414, a dual inhibitor of class I phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) in patients with advanced solid tumors

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.3091-3091

2019

Volltextzugriff (PDF)

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Anti-Ferroportin Antibody in Patients with Anemia Due to Chronic Renal Failure

Blood, 2016-12, Vol.128 (22), p.1280-1280

2016

Volltextzugriff (PDF)

Children’s strategies in complex arithmetic

Journal of experimental child psychology, 2008-11, Vol.103 (1), p.49-65

2008

Volltextzugriff (PDF)

Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)

Investigational new drugs, 2013-08, Vol.31 (4), p.1023-1034

2013

Volltextzugriff (PDF)

Logs Analysis of Adapted Pedagogical Scenarios Generated by a Simulation Serious Game Architecture

International journal of game-based learning, 2017-04, Vol.7 (2), p.1-19

2017

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(46)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer

Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma

A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia

Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study

Elimination of [14C] LY3023414 by aldehyde oxidase and CYP enzymes in humans following oral administration

Oral Administration of Gemcitabine in Patients with Refractory Tumors: A Clinical and Pharmacologic Study

Association of Long-term Administration of the Survivin mRNA-Targeted Antisense Oligonucleotide LY2181308 With Reversible Kidney Injury in a Patient With Metastatic Melanoma

Children’s strategies in complex arithmetic

Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship

Targeting the hepcidin–ferroportin pathway in anaemia of chronic kidney disease

Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer

Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials

A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979)

A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer

First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

Abstract P142: Preclinical characterization of LOX-22783, a highly potent, mutant-selective and brain-penetrant allosteric PI3Kα H1047R inhibitor

A Randomised Phase 2 Study Combining LY2181308 Sodium (Survivin Antisense Oligonucleotide) with First-line Docetaxel/Prednisone in Patients with Castration-resistant Prostate Cancer

Safety and tolerability of the dual PI3K/mTOR inhibitor LY3023414 in combination with fulvestrant in treatment refractory advanced breast cancer patients

Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone

A phase Ib study of prexasertib, a checkpoint kinase (CHK1) inhibitor, and LY3023414, a dual inhibitor of class I phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) in patients with advanced solid tumors

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Anti-Ferroportin Antibody in Patients with Anemia Due to Chronic Renal Failure

Children’s strategies in complex arithmetic

Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)

Logs Analysis of Adapted Pedagogical Scenarios Generated by a Simulation Serious Game Architecture

Suchergebnisse filtern